CVS

CVS HEALTH
D

CVS

Arincen56/100B
83.870
USD
2.53
(3.11%)
Post Trading·84.200USD+0.330(+0.39%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q3 FY2026 results
EPS2.09+26.7%Revenue108.40B+3.5%
OverviewFinancialsNewsForecastEarningsDividendsCompany

CVS HEALTH executives and insider trading

J. David Joyner CEBS reported no open-market purchases or sales over the last twelve months.

Over the last twelve months CVS HEALTH's insiders sold 3,819,551 shares for 345.74M USD in 9 sales on the open market, and bought 23,855 shares in 1 purchases.

Insiders over the last twelve months

Insider sales
9
Shares sold
3,819,551
Value sold
345.74M USD
Insider purchases
1

Insiders buying against selling

Bought on the market
Sold on the market
2.00M USD
1 week
0
2.00M USD
1 month
0
2.00M USD
3 months
0
2.00M USD
6 months
339.50M USD
2.00M USD
1 year
345.74M USD
2.10M USD
2 years
346.27M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Larry Robbins Director—3,750,000339.50M USD—21 May 20264,824,799
Tilak Mandadi EVice President of Ventures and Chief Experience & Technology Officer6269,5516.23M USD—8 May 202610,133
Prem S. Shah Executive Vice President & Group President46——23,855—88,516

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
6 Nov 2026Prem S. ShahPurchase23,85583.902.00M USD88,516Form 4
21 May 2026Larry RobbinsSale370,46293.4534.62M USD4,824,799Form 4
21 May 2026Larry RobbinsSale378,00058.2922.03M USD—Form 4
20 May 2026Larry RobbinsSale797,62893.4874.56M USD5,415,633Form 4
20 May 2026Larry RobbinsSale152,69194.8114.48M USD5,262,942Form 4
20 May 2026Larry RobbinsSale66,88195.676.40M USD5,196,061Form 4
20 May 2026Larry RobbinsSale80096.2877.03K USD5,195,261Form 4
19 May 2026Larry RobbinsSale1,983,38794.45187.33M USD6,213,412Form 4
19 May 2026Larry RobbinsSale15195.1814.37K USD6,213,261Form 4
8 May 2026Tilak MandadiSale69,55189.586.23M USD10,133Form 4
20 Aug 2025Anne A. FinucaneSale7,50071.02532.65K USD22,156Form 4
5 Jun 2025Guy P SansonePurchase1,57063.70100.01K USD12,007Form 4
23 Jan 2025Steven Hale NelsonPurchase2453.701.29K USD24Form 4

Common questions about CVS HEALTH's executives and insiders

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.